News

Featured news

Q3 FY25 Investor Briefing
7 May 2025

Lumos CEO and MD, Doug Ward, and CFO, Barrie Lambert, this week presented the Company's Q3 FY25 quarterly results...

Lumos secures additional US Medicare reimbursement coverage for FebriDx®
23 April 2025

Lumos has announced that it has received confirmation of Medicare reimbursement coverage from two additional Medicare Administrative Contractors (MACs)...

Lumos secures US Medicare reimbursement coverage for FebriDx®
17 April 2025

Lumos has announced that it has achieved a series of important reimbursement milestones in the US...

All news
Q3 FY25 Investor Briefing
7 May 2025

Lumos CEO and MD, Doug Ward, and CFO, Barrie Lambert, this week presented the Company's Q3 FY25 quarterly results...
Quarterly Activity Statement & 4C | Period ending 31 March 2025
29 April 2025

Lumos Diagnostics (ASX:LDX) has released its quarterly report for the period ending 31 March 2025....
Lumos secures additional US Medicare reimbursement coverage for FebriDx®
23 April 2025

Lumos has announced that it has received confirmation of Medicare reimbursement coverage from two additional Medicare Administrative Contractors (MACs)...
Lumos secures US Medicare reimbursement coverage for FebriDx®
17 April 2025

Lumos has announced that it has achieved a series of important reimbursement milestones in the US...
VIDEO |1H FY25 Results Investor Briefing
5 March 2025

Lumos CEO and MD, Doug Ward, and Chief Financial Officer, Barrie Lambert, held an investor briefing this week...
Lumos Announces Expanded Scope of Work under Hologic fFN Development Agreement
3 March 2025

Lumos Diagnostics has announced an agreement to expand the scope of work under the Development Agreement...
FebriDx® Featured in Australian Doctor
14 February 2025

General practitioners (GPs) routinely assess conflicting symptoms of respiratory illness in their patients - and on the balance of available information and clinical judgement, often prescribe antibiotics on the spot...
Video | Q2 FY25 Investor webinar
5 February 2025

Lumos CEO Doug Ward and CFO Barrie Lambert present the Company's latest quarterly performance...
Lumos Diagnostics receives CPT PLA procedure code approval for FebriDx™ in the US
5 December 2024

Lumos has today announced that it has received approval from the Centers for Medicare and Medicaid Services...
Nine News Coverage
21 November 2024

Lumos' FebriDx® was featured on Channel 9 News during its prime time 6pm national bulletin last night...
Lumos Successfully Completes Retail Entitlement Offer
8 October 2024

Lumos Diagnostics has announced that it has successfully completed the retail component of its Entitlement Offer...
Lumos and BARDA to Partner to Support FebriDx® CLIA Waiver Study and Application
3 October 2024

Lumos has been awarded US$2,984,571 from the Biomedical Advanced Research and Development Authority (BARDA)...
Lumos Awarded National Contract with MediGroup for FebriDx®
25 September 2024

Lumos Diagnostics has been awarded placement of their novel POC test, FebriDx®...
Lumos Appoints Thermo Fisher Scientific as US Distributor for FebriDx®
16 September 2024

Lumos Diagnostics has signed an agreement with Fisher Healthcare, a part of Thermo Fisher Scientific...
Lumos Successfully Completes Institutional Component of Entitlement Offer
6 September 2024

Lumos Diagnostics has today announced that it has successfully completed the institutional component...
FY24 Annual Report
27 August 2024

Lumos has today published its Annual Report for FY24...
Video | Q4 FY24 Investor webinar
1 August 2024

Lumos CEO, Doug Ward, Chief Financial Officer, Barrie Lambert, and Senior VP Commercial Operations, Paul Kase...
Lumos Diagnostics Quarterly Activity Statement and Cash Flow Report period ended 30 June 2024
31 July 2024

Lumos Diagnostics has released its Quarterly Report & 4C for the period ending 30 June 2024.
Stockhead | Air supply: The ASX medtechs tackling respiratory illnesses
15 July 2024

Lumos Diagnostics has been included in a Stockhead article spotlighting medtech companies addressing respiratory illness...
Video | Q&A with Paul Kase, SVP, Commercial Operations
12 July 2024

In this Q&A with Paul Kase, Lumos’ SVP, Commercial Operations, Paul outlines how Lumos is working in partnership with Henry Schein...

Subscribe for Lumos news

By entering your email address you are agreeing to our Privacy Policy.

Innovation at the point-of-care

2024 Lumos Diagnostics

Quick links
Engage with us